(Mirabegron + tamsulosin hydrochloride) is under clinical development by DongKoo Bio & Pharma and currently in Phase III for Benign Prostatic Hyperplasia. According to GlobalData, Phase III drugs for Benign Prostatic Hyperplasia have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how (Mirabegron + tamsulosin hydrochloride)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Mirabegron + tamsulosin hydrochloride) overview
DKB-17001 is a fixed dose combination of mirabegron and tamsulosin hydrochloride is under development for the treatment of overactive bladder and benign prostatic hyperplasia. It is an incrementally modified drug. Mirabegron acts by targeting beta adrenergic receptor and tamsulosin hydrochloride acts by targets alpha-1 adrenergic receptor.
DongKoo Bio & Pharma overview
DongKoo Bio & Pharma (DongKoo) is a pharmaceutical company that develops, manufactures and sale generic drugs. The company’s product portfolio includes medicines, prescription drugs, over the counter (OTC) medicines, quasi drugs, medical equipment, cosmetics, among others. The company also provide contract manufacturing services. DongKoo provid products in various therapeutic areas comprise dermatology, urology, antiviral and antibacterial agents, pain management, erectile dysfunction and liver diseases. It also conduct research and development of new drugs and generics, stem cell medical devices, biopharmaceuticals, and cosmeceuticals. The company offers products in various forms, such as soft gelatin capsules, hard capsules, tablets, powders or granules, externals and liquids. DongKoo is headquartered in Seoul, South Korea.
For a complete picture of (Mirabegron + tamsulosin hydrochloride)’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
